Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011

I. Morrissey, H. Seifert, R. Cantón, P. Nordmann, S. Stefani, A.P. Macgowan, R. Janes, Dan Knight, R. Bonnet, C.J. Soussy, R. Courcol, R. Leclercq, R. Zahar, C. Poyart, Y. Rio, W. Pfister, C. Schoerner, F. Albert, E. Jacobs, S. Schubert & 26 others R. Mutters, F.J. Schmitz, F.A. Luzzaro, E. Manso, C. Scarparo, G. Fadda, F. Rossano, G.M. Rossolini, G.P. Gesu, M.P. Landini, L. Martínez, J.L. Pérez, C. Gimeno, A. Pascual, J. Liñares, R. Bartolomé, R. Cisterna, K. Gould, M. Dryden, M.J. Weinbren, A. Swann, M. Wilcox, G. Moore, J. Andrews, J. Ashby, S. Kaul

    Research output: Contribution to journalArticle

    22 Citations (Scopus)

    Abstract

    Objectives: To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe. Methods: Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined. Results: Oritavancin was very active against MRSA (MIC50/MIC90 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis). Conclusions: These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents. © The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
    Original languageEnglish
    Pages (from-to)164-167
    JournalJournal of Antimicrobial Chemotherapy
    Volume68
    Issue number1
    DOIs
    Publication statusPublished - 2013

      Fingerprint

    Cite this